Summary & Overview
HCPCS J7516: Injection, Cyclosporine 250 mg
HCPCS Level II code J7516 designates an injection of cyclosporine, 250 mg, a systemic immunosuppressant used in various transplant and autoimmune contexts. Nationally, accurate reporting of injectable drug HCPCS codes is essential for clinical documentation, claims processing, and pharmacy benefit coordination because high-cost biologic and specialty medications drive payer scrutiny and utilization management.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how this code is used in ambulatory and infusion settings, common billing considerations for drug administration claims, and the clinical contexts in which cyclosporine injections are relevant. The publication also outlines benchmark elements and policy considerations that affect coverage and reimbursement for parenteral immunosuppressant therapies.
This summary provides national-level context for revenue cycle leaders, coding professionals, and clinical pharmacists seeking clarity on coding practices for injectable cyclosporine. It highlights service settings, documentation priorities, and the broader payer landscape without prescribing clinical or billing actions.
Billing Code Overview
HCPCS Level II code J7516 describes an injection of cyclosporine, 250 mg. This code denotes a single drug administration service for the systemic immunosuppressant cyclosporine in a 250 mg dose.
Service type: Drug administration / injectable therapy
Typical site of service: Outpatient infusion clinic, outpatient hospital department, physician office, or other ambulatory settings where parenteral medications are administered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related billing lines.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J7516 (injection, cyclosporine, 250 mg) is an adult or pediatric patient with an autoimmune or inflammatory condition requiring systemic immunosuppression when oral therapy is contraindicated, not tolerated, or when parenteral dosing is required for rapid therapeutic effect. Examples include severe refractory uveitis, moderate-to-severe psoriasis with poor oral absorption, or organ transplant recipients when intravenous cyclosporine is used in induction or for acute rejection management.
The clinical workflow begins with an outpatient specialty or inpatient consult (dermatology, ophthalmology, transplant medicine, or rheumatology). The provider documents indication, weight-based dosing or fixed dosing plan, informed consent, and baseline laboratory studies (renal function, electrolytes, drug levels when applicable). Pharmacy prepares the J7516 dose as an injectable formulation; administration may occur in an infusion suite, outpatient clinic, ambulatory surgical center, or inpatient unit depending on indication and monitoring needs. Vital signs and infusion reaction monitoring occur during and after administration. Post-administration documentation includes lot number, amount administered, any unused drug discarded (with modifier JW if applicable), patient tolerance, and follow-up plan for monitoring drug levels and renal function.
Coding Specifications
| Modifier | Description | When to Use |
|---|